1109277-67-9Relevant academic research and scientific papers
Construction of Morphan Derivatives by Nitroso–Ene Cyclization: Mechanistic Insight and Total Synthesis of (±)-Kopsone
Zhai, Li,Tian, Xuechao,Wang, Chao,Cui, Qi,Li, Wenhua,Huang, Sha-Hua,Yu, Zhi-Xiang,Hong, Ran
, p. 11599 - 11603 (2017)
A type II nitroso–ene cyclization was developed for the construction of morphan derivatives with good functional-group tolerance. DFT calculations revealed that the nitroso–ene reaction proceeds in a stepwise manner involving diradical or zwitterionic intermediates. The rate-determining step is C?N bond formation, followed by a rapid hydrogen-transfer step with a chair-conformation transition state. The current approach was also successfully applied in the first total synthesis of (±)-kopsone, a highly strained yet simple morphan-type alkaloid isolated from Kopsia macrophylla.
GLP-1R AGONISTS AND USES THEREOF
-
Page/Page column 59; 115, (2020/10/21)
Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
PYRIDINE DERIVATIVES AS DGAT-1 INHIBITORS
-
, (2014/09/29)
Described herein are compounds of formula (I): The compounds of formula (I) act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
-
Page/Page column 198, (2014/02/15)
A series of imidazo[l,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS
-
Page/Page column 793, (2014/09/29)
Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)
SUBSTITUTED BICYCLOLACTAM COMPOUNDS
-
Page/Page column 18, (2009/03/07)
The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c, R5d, Q, A, Z, and R7 /s
